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Rho GTPases are key regulators of the actin-based
cytoskeleton; Rab GTPases are key regulators of
membrane traffic. We report here that the atypical
RhoGTPase familymember,RhoBTB3,bindsdirectly
to Rab9 GTPase and functions with Rab9 in
protein transport from endosomes to the trans Golgi
network. Gene replacement experiments show that
RhoBTB3 function in cultured cells requires both
RhoBTB30s N-terminal, Rho-related domain and
C-terminal sequences that are important for Rab9
interaction. Biochemical analysis reveals that
RhoBTB3 binds and hydrolyzes ATP rather than
GTP.Rab9binding opens the autoinhibitedRhoBTB3
protein to permit maximal ATP hydrolysis. Because
RhoBTB3 interacts with TIP47 on membranes, we
propose that it may function to release this cargo
selectionprotein fromvesicles topermit their efficient
docking and fusion at the Golgi.
INTRODUCTION
Rho GTPases are key regulators of the actin-based cytoskeleton
and thus control most aspects of cell dynamics, including migra-
tion, division, and morphogenesis (Jaffe and Hall, 2005; Ridley,
2006). There are at least 20 members of this subfamily of Ras-
like GTPases in humans, and although many have been studied
in great detail, the so-called atypical Rho GTPase subset are
much less well understood (Salas-Vidal et al., 2005; Aspenstro¨m
et al., 2007). Three atypical Rho GTPases, RhoBTB1, 2, and 3,
are much larger (67–83 kDa) than conventional Rho proteins
and are comprised of N-terminal, Rho-related domains followed
by one or more BTB (Bric-a-brac, Tramtrack, Broad-complex)
domains (Figure 1; Ramos et al., 2002; Berthold et al., 2008a).
BTB domains are found in about 200 proteins and are thought
to mediate protein:protein interactions.
RhoBTB1 and RhoBTB2 show 79% similarity in sequence and
are likely orthologs of the single RhoBTB that is present in Dic-
tyostelium, Drosophila, and Anopheles (Ramos et al., 2002).
RhoBTB2 has attracted attention as a tumor suppressor that is
downregulated in several tumor types (Hamaguchi et al., 2002;
Berthold et al., 2008a). RhoBTB20s first BTB domain interacts
with the Cullin3 ubiquitin ligase scaffold protein, and Wilkins938 Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc.et al. (2004) have proposed that RhoBTB2 acts as a tumor
suppressor by recruiting substrates to a Cul3 ubiquitin ligase
complex for degradation. Like most Rho proteins (Ridley,
2006), changes in RhoBTB2 levels also influence membrane
trafficking pathways (Siripurapu et al., 2005; Chang et al.,
2006), and both RhoBTB1 and 2 are associated with what
appear to be late endosomes or lysosomes in cultured cells
(Aspenstro¨m et al., 2004).
RhoBTB3 is likely to play a different role than RhoBTB1 and 2,
as it is the most divergent of the three RhoBTB proteins (only
48% similar to RhoBTB1 and 2), and residues that are key for
RhoBTB2-Cul3 interaction (including Y248) are not present in
RhoBTB3 (but see Berthold et al., 2008b). Moreover, RhoBTB3
is only found in vertebrates but, like RhoBTB1, appears to be
expressed in all tissues analyzed (Ramos et al., 2002). Indeed,
Boureux et al. (2007) do not classify RhoBTB3 as a Rho family
member, but the conserved domain database identified
RhoBTBs 1, 2, and 3 as containing ‘‘RhoBTB’’ domains, a subset
of Rho domains (Marchler-Bauer et al., 2007).
We study the transport of mannose 6-phosphate receptors
(MPRs) from late endosomes to the Golgi complex. This process
requires Rab9 GTPase (Lombardi et al., 1993; Riederer et al.,
1994), the cargo selection protein and Rab9-localizer, TIP47
(Diaz and Pfeffer, 1998; Aivazian et al., 2006), cytoplasmic dynein
(Itin et al., 1999), the trans Golgi network (TGN)-localized tethering
protein, GCC185 (Reddy et al., 2006; Derby et al., 2007), Rab6
and Arl1 GTPases (Burguete et al., 2008), and a SNARE complex
comprised of Syntaxin 10, Syntaxin 16, Vti1a, and VAMP3 (Gan-
ley et al., 2008). As part of our ongoing efforts to elucidate the
molecular mechanism of this trafficking pathway, we carried
out a yeast two-hybrid screen to identify gene products that
interact preferentially with Rab9-GTP (Reddy et al., 2006). We
report here the characterization of a novel Rab9 effector identified
in that screen: RhoBTB3. To our surprise, this protein turns out to
be a Rab9-regulated ATPase, rather than a GTPase, that partici-
pates in transport vesicle docking at the Golgi complex.
RESULTS
RhoBTB3 is a 611 amino acid protein that contains a Rho
GTPase-related domain near its N terminus and a BTB domain
near its C terminus, as annotated by the conserved domain data-
base (Marchler-Bauer et al., 2007) (Figure 1A). The related
RhoBTB1 and RhoBTB2 proteins are shown for comparison
(Figures 1A and 1B). The Rho domains of these two proteins are
more closely related to the canonical RhoA protein (37% and
39%, respectively). In addition, they appear to have a remnant of
a second BTB domain, although sequence similarity algorithms
that include structural information, such as the conserved domain
architecture retrieval tool (Marchler-Bauer et al., 2007), indicate
that each of these proteins contains only one intact BTB motif.
Unlike RhoBTBs 1 and 2, RhoBTB30s C-terminal sequence termi-
nates in a consensus prenylation sequence, CAAX.
RhoBTB3 was identified in a yeast two-hybrid screen for Rab9-
GTP-interacting proteins. Binding was quantified by liquid culture
analysis: full-length RhoBTB3 interacted with the GTP conforma-
tion of Rab9 (Rab9Q66L) but not a mutant Rab9 that binds GDP
with 50-fold preference to GTP (Rab9S21N; Riederer et al.,
1994) (Figure 2A). Binding was also specific, as no interaction
was seen for the activated mutant forms of Rabs 5 (Rab5 Q79L)
or 7 (Rab7 Q67L). Subsequent analysis of 54 different Rab
GTPases confirmed binding specificity: only Rab9A and, to
a lesser extent, Rab9B showed interaction with RhoBTB3
(Figure S1 available online). We will focus here on Rab9A (‘‘Rab9’’).
Truncation constructs were generated to identify the precise
Rab9-binding site within RhoBTB3. As shown in Figure 2B, the
Rab9-binding site was localized to the C-terminal region of the
protein, as residues 420–611 were sufficient to yield full b-galac-
tosidase activation in the two-hybrid system.
RhoBTB3 Is a Rab9 Effector and Localized to the Golgi
To verify that the binding observed in yeast was due to a direct
protein:protein interaction, we tested the ability of purified GST-
RhoBTB3 C-terminal residues 420–611 to bind purified Rab
proteins. Rabs were preloaded with GTPg-[35S] or [3H]-GDP
and then incubated with RhoBTB3; bound proteins were
collected on glutathione beads and counted in a scintillation
counter. As shown in Figure 2C, RhoBTB3 bound saturably to
Figure 1. Alignment of RhoBTB3 with RhoBTBs 1 and
2 and RhoA
(A) Amino acid residues are listed at the top; numbers at left
indicate RhoBTB1, 2, or 3. Each of the proteins has an
N-terminal Rho domain (red) and at least one intact BTB
domain (blue). Because RhoBTB has a single ancestor closest
to RhoBTB1 and 2, the conserved domain database identified
these as ‘‘RhoBTB’’ domains, a subset of Rho domains
(Marchler-Bauer et al., 2007). RhoBTB3 is unique with
a C-terminal CAAX prenylation motif (CLVM shown).
(B) Sequence alignment of RhoBTB30s Rho domain with RhoA
and the Rho domain of RhoBTB2. Canonical features of
typical GTPases are noted (G1 P loop, G2, G3, and G4). Arrow
points to Asn138. In all GTPases, this residue is Asp and
confers specificity for guanosine.
Rab9 but not Rab5, and binding showed strong
preference for Rab9-GTP (Figure 2D).
Error-prone PCR mutagenesis was carried out to
further define RhoBTB3 residues important for
Rab9 binding; mutated constructs were screened
for loss of interaction by two-hybrid analysis and
then sequenced directly. These screens suggested
that Rab9 interaction required A498, D532, or I533
(Figure 1B) as their mutation abolished binding in
the two-hybrid system (not shown). The D532E
mutation was of particular interest, as that residue is a glutamic
acid in RhoBTB2. The importance of D532 for Rab9 binding
was demonstrated directly: purified RhoBTB3 D532E protein
(2E gel inset) showed significantly less binding to Rab9 than
wild-type protein, confirming the importance of this region of
the protein in Rab9 interaction (Figure 2E).
RhoBTB3 is localized to the Golgi complex, as determined by
indirect immunofluorescence of myc-RhoBTB3 transfected
cells, using the proteins TGN46 or GCC185 as endogenous Golgi
marker proteins (Figure S2; see also Berthold et al., 2008b).
Confirmation of this localization was obtained by disruption of
the microtubule-based cytoskeleton using nocodazole. Under
these conditions, the Golgi fragments into mini-stacks that
distribute throughout the cytoplasm. The Golgi marker, TGN46,
showed complete colocalization with RhoBTB3 under control
and nocodazole conditions. Thus, myc-RhoBTB3 appears to
be Golgi associated. Unfortunately it was not possible to detect
endogenous RhoBTB3 by light microscopy using two separate
rabbit antisera raised against recombinant RhoBTB3 protein;
these only detected endogenous protein by immunoblot.
The localization of RhoBTB3 to the Golgi did not require
C-terminal residues that could potentially be prenylated, as a
DCAAX mutant was not altered in its subcellular localization
(see below). In addition, Rab9 does not determine RhoBTB30s
Golgi association as most Rab9 is not found on the Golgi, and
a mutant form of RhoBTB3 (D532E) that cannot bind Rab9 is nor-
mally localized (see below).
RhoBTB3 Is Required for Retrograde Transport
to the Golgi Complex
Because of the close link between Rho GTPases and the actin
cytoskeleton, we first tested whether depletion or overexpressionCell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc. 939
Figure 2. RhoBTB3 Interacts Specifically
with Rab9 GTPase via Its C Terminus
(A) Liquid culture b-galactosidase activity of yeast
strains coexpressing the clone 8-GAL4 activation
domain (RhoBTB3 131–607) hybrid and GAL4-
DNA binding domain hybrids of either Rab9Q66L,
Rab9S21N, Rab7Q67L, or Rab5Q79L.
(B) Liquid culture of b-galactosidase activity of
yeast strains coexpressing the indicated RhoBTB3
fragments with the GAL4-DNA binding domain of
Rab9Q66L. Error bars in (A) and (B) represent stan-
dard deviation of duplicate determinations from
a representative experiment. RhoBTB3 C terminus
(420–607) was subjected to PCR-based mutagen-
esis and assayed for subsequent Rab9 binding by
two-hybrid screening; point mutations that abol-
ished Rab9 binding are indicated.
(C) (Left panel) Increasing amounts of purified GST-
RhoBTB3 C terminus (amino acids [aa] 420–611)
were incubated with purified Rab9 or Rab5
(600 nM), preloaded with 35S-GTPgS. Inset, SDS-
PAGE of proteins used for these experiments.
(D) GST-RhoBTB3C terminus (aa420–611; 180nM)
binding to Rab9 bearing either 35S-GTPgS- or
3H-GDP as in (C). Error bars represent standard
deviation.
(E) Binding of full-length wild-type or RhoBTB3
D532E proteins (100 nM) to Rab9-GTP (3mM). Inset
at right shows Coomassie-stained SDS-PAGE of
the proteins used. Asterisk indicates His-RhoBTB3
full length.of RhoBTB3 altered the appearance of either actin or microtu-
bules. Superficial examination of light micrographs did not reveal
any significant changes (not shown). To try to determine
RhoBTB30s function, we took advantage of the clue that it binds
to Rab9 GTPase.
Rab9, and each of its effectors that have been studied to date
(p40, GCC185, TIP47), are required for the recycling of MPRs
from endosomes to the TGN. To test if RhoBTB3 is also involved
in this process, we used siRNA-mediated protein depletion and
monitored the distribution of MPRs in siRNA-transfected cells.
MPRs normally display a tight perinuclear localization, adjacent
to the Golgi complex (Figure 3A, left panel). When another
Golgi-localized Rab9 effector, GCC185, is depleted from cells,
MPRs accumulate in peripheral, Rab9-positive transport inter-
mediates (Reddy et al., 2006). This has implicated GCC185 as
a tethering factor in this transport process.
Upon siRNA depletion of RhoBTB3, MPRs appeared in small
dispersed vesicles throughout the cytoplasm, reminiscent of
the phenotype observed upon GCC185 depletion (Figures 3A
and 3B; Reddy et al., 2006). The phenotype was quantified by
determining the percent of total MPR intensity detected at
various distances from the center of intensity. Using this metric,
the distribution of MPRs in depleted cells (Figure 3C, dark bars)
was demonstrably broader than in control cells (Figure 3C, light
bars). Although GCC185 was slightly altered in its appearance
(see below), the Golgi remained intact in cells depleted of
RhoBTB3 (Figure 3B). In contrast to GCC185 and analogous to
MPRs, TGN46 proteins were also broadly distributed (Figures
3A and 3D). It is important to note that unlike GCC185, TGN46
cycles between endosomes and the Golgi. These data suggest940 Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc.that RhoBTB3 is needed for the retrograde transport of both
MPRs and TGN46 to the Golgi complex; in its absence, cycling
proteins are unable to return.
If RhoBTB3 functions in transport vesicle tethering, cells
depleted of this protein should accumulate MPRs in Rab9-posi-
tive transport intermediates. To test this, cells stably expressing
GFP-Rab9 were depleted of RhoBTB3 and the localization of
MPRs and Rab9 GTPase in peripheral vesicles was quantified.
As shown in Figure 3E, a large proportion of peripheral, small
vesicles carrying MPRs were indeed Rab9 positive (>80%).
These structures were not early or recycling endosomes as
they did not contain fluorescent transferrin, endocytosed for
15 min (Figure S3), or the early endosome marker, EEA1 protein
(Figure 3E). The accumulation of MPRs in Rab9-positive struc-
tures that are not early endosomes is consistent with a role for
RhoBTB3 in transport vesicle tethering at the Golgi complex. In
addition, 95% of dispersed TGN46 was not in the same vesi-
cles as MPRs, consistent with their accumulation in a different
type of transport vesicle carrier (Figure 3E). Unlike MPRs,
TGN46 recycling requires Syntaxin 6 (Ganley et al., 2008). Given
the distinct biochemical requirements for TGN46 recycling, its
accumulation in a distinct type of vesicle is not unexpected;
however both TGN46 and MPRs require RhoBTB3 function
upon arrival at the Golgi complex.
Careful examination of cells depleted of RhoBTB3 showed
that the Golgi (monitored by GCC185 localization) appeared
somewhat enlarged compared with control cells. This was quan-
tified by determining the number of pixels occupied by the Golgi
marker under various conditions (Figure 4A). In control cells,
GCC185 occupied 2889 ± 109 pixels per cell (n = 210). In
Figure 3. Depletion of RhoBTB3 Disperses MPRs into Peripheral,
Rab9-Positive Vesicles
(A) Cells depleted of RhoBTB3 mis-sort the cycling protein TGN46 (red) as well
as CI-MPR (green). White lines represent approximate cell outlines.
(B) Endogenous GCC185 remains on the Golgi in RhoBTB3-depleted cells.
Scale Bar is 10 mm.
(C) Fluorescence intensity distribution of CI-MPR in control (n = 20) and
RhoBTB3-depleted cells (n = 23) was quantified using ImageJ. Circles of
different radii, centered on the peak fluorescent signal, were drawn; the inten-
sity within each ring of the bull’s eye was quantified relative to the total intensity
in the cell. Shown is the percent CI-MPR intensity in the central 0–60 pixel
region, the next region 61–101 pixels from the center, or the next 102–150
pixels from the center.
(D) Intensity distribution of TGN46 was measured as in (C) (n = 13 for control
and RhoBTB3 depletion). Inset, western blot showing RhoBTB3 depletion
upon siRNA treatment.
(E) Peripheral MPR containing vesicles are Rab9 positive but do not contain
TGN46 or EEA1. BsC-1 cells stably expressing GFP-Rab9 were depleted ofdepleted cells, this almost doubled to 5764 ± 453 pixels per cell
(n = 44), even though overall cell size remained unchanged. A
similar expansion was seen for the Golgi marker, p115 (data
not shown). Expression of the RhoBTB3 N138D mutant that
cannot bind nucleotide (see below) caused a smaller increase
in Golgi area (4195 ± 323 [n = 60]), but expression of wild-type
RhoBTB3 did not (Figure 4A). For comparison, depletion of
GCC185, which causes the Golgi to fragment into mini-stacks
(Reddy et al., 2006), did not change the overall area occupied
by the Golgi complex, as monitored by the area occupied by
Golgin-245 protein (Figure 4A). Thus, RhoBTB3 also contributes
to the overall structure of the Golgi complex.
Consistent with a role in MPR transport, cells depleted of
RhoBTB3 showed a 2-fold increase in the secretion of the lyso-
somal hydrolase, hexosaminidase (Figure 4B), despite compa-
rable levels of total enzyme in controls and siRNA-depleted cells
(both 5.2 3 103 units/mg hexosaminidase). In addition, the
steady-state levels of MPRs increased at least 2-fold (Figure 4C).
These are hallmarks of a block in MPR trafficking (Riederer et al.,
1994) and are seen in cells expressing the GDP-preferring mutant
of Rab9 (S21N) or depleted of Rab9 (Ganley et al., 2004), GCC185
(Reddy et al., 2006), or Syntaxin 10 proteins (Ganley et al., 2008).
Specifically, when MPRs are mis-sorted to lysosomes they are
turned over more rapidly; in several cases, cells compensate
for this loss by upregulating MPR synthesis.
To confirm a specific role for RhoBTB3 in MPR transport to the
Golgi complex, we tested whether anti-RhoBTB3 antibodies
could inhibit this transport process in an in vitro system that
reconstitutes this transport event (Itin et al., 1999). Anti-RhoBTB3
IgG inhibited transport 40% under conditions in which preim-
mune IgG inhibited less than 10% (Figure 4D). Similarly, negative
control anti-Syntaxin 6 antibodies inhibited 10% while another
positive control antibody, anti-Rab9, also inhibited 40% (Ganley
et al., 2008). These data support the conclusion that RhoBTB3
function is needed for MPR transport to the Golgi complex both
in vitro and in live cells. As mentioned earlier, the anti-RhoBTB3
antibody does not readily recognize the native protein upon
immunofluorescence of fixed cells, which could easily explain
the incomplete block of in vitro transport observed.
The specificity of RhoBTB30s role in retrograde transport was
confirmed by monitoring general endocytosis and exocytosis in
RhoBTB3-depleted cells. Transferrin uptake and recycling in
RhoBTB3-depleted cells was indistinguishable from that seen
for control cells (Figure 4E). In addition, in RhoBTB3-depleted
cells, the rates of export of VSV-G glycoprotein from the endo-
plasmic reticulum, its transit through the Golgi complex, and its
arrival at the cell surface were entirely unchanged (Figure 4F). In
summary, these data show that RhoBTB3 functions specifically
in retrograde transport from endosomes to the Golgi complex
and in maintenance of the structure of the Golgi complex.
Although the Golgi was slightly larger in area (Figure 4A), it was
nevertheless fully functional for G-glycoprotein export.
RhoBTB3. Peripheral vesicles were scored for the presence of MPRs and
Rab9 as in (A) and (B). An example is shown at right. HeLa cells were used
to score TGN46 and EEA1 (examples at right). In all experiments, depletion
was for 72 hr. Error bars represent standard deviation in (C), (D), and (E);
data were from multiple experiments for each panel.Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc. 941
RhoBTB3 Function Requires Its Rho-Related Domain
and Rab9-Binding Capacity
We identified two mutant proteins that blocked either RhoBTB30s
nucleotide-binding capacity (N138D, see below) or its ability to
interact with Rab9 GTPase (D532E). Thus we could test the
importance of these distinct domains on RhoBTB30s role in
MPR transport to the Golgi complex. For these experiments,
we used fluorescent siRNA to deplete RhoBTB3 from cells and
enable their identification. We then carried out gene rescue
experiments with either myc-tagged, wild-type RhoBTB3 or
one of three mutant versions, each of which carried eight silent
mutations to mask the rescuing construct from siRNA-mediated
destruction.
In Figure 5 (right column), fluorescent siRNA-containing cells
are marked with an asterisk. They are depleted of endogenous
RhoBTB3 based upon the high potency of the siRNA (Figure 3D)
and the dispersal of MPRs detected. In the top row, RhoBTB3-
depleted cells that also received a wild-type rescue plasmid (left
column, two cells at left) showed a concentrated, perinuclear
MPR distribution. In contrast, the right-most cell that expressed
much less of the rescuing protein showed a dispersed MPR
phenotype, as expected for RhoBTB3-depleted cells. Thus, the
Figure 4. RhoBTB3 Depletion Expands the Golgi and
Blocks MPR Trafficking
(A) Quantitation of Golgi area. Left, GCC185 area in control cells (n =
210), cells depleted of RhoBTB3 (n = 44), or cells expressing wild-
type RhoBTB3 (n = 42) or N138D RhoBTB3 (n = 60) was quantified
using a Matlab script. Right, Golgi area in control cells (n = 48) or in
cells depleted of GCC185 (n = 67) using Golgin-245 staining.
(B) Lysosomal enzyme secretion upon depletion of RhoBTB3.
Cells were treated for 72 hr with siRNA against RhoBTB3 and
assayed for secretion of hexosaminidase. Both control and
depleted cells contained 5.2 3 103 units/mg hexosaminidase.
(C) Immunoblot analysis of CI-MPR levels in control or RhoBTB3-
depleted cell extracts; 10 or 20 mg of HeLa extracts were analyzed
as indicated.
(D) MPR transport from endosomes to the TGN (Reddy et al.,
2006) was carried out for 90 min in the presence or absence of
the indicated amounts of nonimmune or rabbit anti-RhoBTB3
IgG. In (A), error bars represent standard error of the mean; in
(B) and (D), standard deviation of duplicate samples from a repre-
sentative experiment are shown.
(E) Alexa-594-Transferrin (50 mg/ml) was prebound to cells on ice
for 60 min; cells were warmed for various times and cell-associ-
ated transferrin was determined after washing with 20 mM
HOAC (pH 3), 500 mM NaCl by immunofluorescence and MatLab
analysis in control and RhoBTB3-depleted HeLa cells (>50 cells
counted for each time point in two separate experiments; average
of both is shown).
(F) YFP-VSV-G-ts045 transport through the ER, Golgi, and cell
surface was carried out as described (Sklan et al., 2007) for
control and RhoBTB3-depleted cells, with >150 cells counted at
each time point, in two separate experiments, one of which is
shown. The two data sets were identical.
wild-type construct can restore the normal, compact
perinuclear MPR distribution. Similar data were
obtained for the RhoBTB3 DCAAX mutant (Figure 5,
bottom row). Again, the presence of the rescue plasmid
was sufficient to normalize MPR localization. It is impor-
tant to note that the CAAX motif may not be modified in cells,
which would represent a trivial explanation for its lack of impor-
tance for either RhoBTB3 localization or rescue.
This was in contrast to cells that were rescued with the
RhoBTB3 N138D construct (second row). Loss of RhoBTB3 in
the two asterisked cells expanded the Golgi, as monitored by
the localization of myc-N138D at left. Despite the presence of the
mutant protein in the two lower cells, MPRs remained dispersed.
Thus, RhoBTB30s Rho domain functionality is required for its
ability to facilitate MPR recycling to the Golgi.
Similarly, the RhoBTB3 D532E rescue plasmid was also
unable to correct a dispersed MPR phenotype in most cells
analyzed (Figure 5, third row). This suggests that either
Rab9 or another interacting partner must be able to link to
RhoBTB3 via this site for it to carry out its proper cellular
function.
Quantitation of these data confirmed that rescue by the wild-
type or DCAAX RhoBTB3 proteins could restore a normal MPR
phenotype to 66%–70% of cells analyzed. In contrast, the
D532E mutant was less able to rescue the phenotype (33%)
and the N138D mutant was even less functional (17% rescue).
Any rescue by the D532E or N138D mutants might be explained942 Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc.
by retention of some Rab9-binding capacity and/or high enough
expression to permit low basal ATP hydrolysis by RhoBTB3
protein.
RhoBTB3 Is an ATPase
GTPases contain signature features that reflect the binding and
hydrolysis capacities of these enzymes (Sprang, 1997). The
Figure 5. RhoBTB3 Function Requires Its ATPase Activity and Ability
to Bind Rab9
RhoBTB3 was depleted by siRNA for 72 hr. Indicated rescue myc-RhoBTB3
constructs were expressed for 48 hr. Top, expression of the wild-type
RhoBTB3 is sufficient to relocalize CI-MPR back to its tight perinuclear
staining. Asterisked cells received fluorescent siRNA. Second, expression of
N138D, a mutant RhoBTB3 that cannot bind or hydrolyze nucleotide, cannot
rescue CI-MPRs back to the perinuclear region. Third, expression of D532E,
a mutant RhoBTB3 that lacks capacity to bind Rab9, also does not
rescue CI-MPR. Bottom, expression of DCAAX, a mutant RhoBTB3 that lacks
the C-terminal prenylation sequence, is capable of rescue. White lines are
approximate cell outlines. Scale bar is 10 mm. Quantitation at bottom
was determined for >100 cells from multiple experiments under each condi-
tion; error bars represent standard deviation. Null samples were mock
transfected.phosphate binding or P loop and elements G2, G3, and G4 are
indicated in Figure 1B. First, note that RhoBTB3 contains an
unusual 16 residue insert in the middle of the P loop. P loops often
contain multiple glycine residues that are thought to generate
flexibility. In RhoBTB3, Pro-Ser-Gly-Leu occupies the middle of
the extended loop and is predicted to create a tight, type II
b-turn (Ybe and Hecht, 1996). This insert could permit extension
of the P loop without disrupting critical contacts with nucleotide.
In addition, the canonical K(S/T) residues of the G1/Walker motif
consensus sequence are replaced with RS in RhoBTB3, which
will maintain charge at that position. A magnesium ion is coordi-
nated by G2 sequences; in RhoBTB3, phenylalanine and gluta-
mic acid replace proline and valine residues conserved between
RhoA and RhoBTB2. Theoretically, these changes might still
accommodate magnesium binding. RhoBTB30s G3 residues
are also poorly conserved. Most small GTPases contain a glycine
residue immediately before the catalytic glutamine in G3; in
RhoA, the sequence is WDTAGQ. RhoBTB3 instead contains
WDIFDS. The significance of these changes is unclear, but as
shown below, RhoBTB3 is capable of nucleotide hydrolysis,
despite the divergence of G3 sequences.
The G4 region determines nucleotide specificity: small GTPases
usually contain the sequence NKXD. Mutation of this aspartic acid
dramatically decreases the ability of GTPases to bind guanosine
nucleotides, and conversion of this residue to asparagine strongly
reduces GTP binding while significantly enhancing xanthosine
triphosphate (XTP) binding to elongation factor Ef-Tu (Hwang
and Miller, 1987) and other small GTPases (Zhong et al., 1995;
Rybin et al., 1996). Because the cell contains very little, if any,
XTP, it was unclear whether RhoBTB3 (with the sequence TRQN
instead of NKXD) could even bind nucleotide; hydrolysis seemed
unlikely, as well. Indeed, Berthold et al. (2008b) reported that
RhoBTB3 cannot hydrolyze GTP. Finally, G5 domain residues
S160, A161, and K162 in RhoA interact with the carbonyl oxygen
on the guanosine base. In RhoBTB3, these SAK residues are
replaced with LDD, which could preclude guanosine interaction.
To test these possibilities directly, we expressed a GST-tagged
RhoBTB3 Rho domain (residues 1–220) and examined the
biochemical characteristics of this domain in vitro.
When small GTPases are expressed in bacteria, they carry with
them bound nucleotide from the bacterial cytoplasm. Thus, after
purification, Ras and Rab GTPases have bound GDP because
GTP is slowly hydrolyzed during protein isolation (cf. Tucker
et al., 1986). Reverse phase HPLC of the purified protein can be
used to both detect and identify bound nucleotide. We first tested
for the presence of bound nucleotide on RhoBTB3.
As expected, reverse phase HPLC confirmed that bacterially
expressed control Rab9 protein carried GDP upon isolation
(dashed profile, Figure 6A). To our surprise, RhoBTB30s Rho
domain carried a substituent that showed absorbance at
254 nm and eluted before GDP; subsequent chromatography
showed precise coelution with an ADP marker. Mass spectro-
scopic analysis of the bound material revealed it to be a mixture
of 80% ADP and 20% dADP (Figure 6B), a ratio of nucleotide to
deoxynucleotide similar to that seen previously for p21 Ras
(Tucker et al., 1986).
The ability of RhoBTB3 to bind ATP was confirmed directly
using the purified Rho domain. Briefly, any already boundCell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc. 943
Figure 6. RhoBTB3 Binds and Hydrolyzes
ATP
(A) Purified proteins were injected onto a reverse
phase HPLC column and nucleotide was eluted.
Purified GST-RhoBTB3 Rho domain (residues
1–220, 5 nmol in 500 ml) (solid profile) released
bound ADP, eluting with a retention time of 177 s.
Rab9 (5 nmol in 500 ml) released bound GDP
(dashed profile), eluting with a retention time 196 s
on this system.
(B) Mass spectroscopy analysis of the peak HPLC
fraction revealed two major peaks at 427 Da and
411 Da. These correspond to the masses of ADP
and dADP, respectively.
(C) RhoBTB3 Rho domain (10 pmol in 100 ml) binds
[a-32P]ATP to saturation; reactions were at 37C
with 100 mM ATP. Error bars represent standard
deviation of duplicates from a representative
experiment.
(D) RhoBTB3 was threaded onto the structure of
RhoA-GMPPNP (PDB 1KMQ) using Modeler 9V3;
steric clash of Van der Waals radii was determined
using UCSF Chimera software. The adenine or
guanine base was rotated 10 outward to relieve
steric clash, and possible hydrogen bonding to
N138 was modeled using Coot software. Left
column, the position of guanine in relation to the
catalytically important N138 and the nearby D180;
right column, adenine. The question mark indicates
possible negative charge repulsion. Hypothetical
hydrogen bond lengths are indicated (dashed lines).
(E) The 10rotated, adenine base of ATP is shown
modeled in the threaded structure; N138 is shad-
owed in green in the space-fill representation.
(F) RhoBTB3 GST-Rho domain binds and hydro-
lyzes ATP and not GTP. Nucleotide-free RhoBTB3
GST-Rho domain (20 nM) was incubated with
different concentrations of [g-32P]ATP or [g-32P]
GTP and MgCl2. A point mutant in the G4 region
of RhoBTB3 (N138D) was also tested.
(G) Initial velocity measurements of ATP hydro-
lysis. Reactions were as in (F) using 600 nM
GST-Rho domain. The first 10% of each reaction
(initial velocity) was plotted as a function of ATP
concentration.nucleotide in the protein preparation was released by EDTA
pretreatment. After desalting, [a32P]-ATP was added and allowed
to bind. As shown in Figure 6C, RhoBTB3 showed saturable
binding of ATP to >80% of molecules added to the reaction.
To gain insight into ATP binding by RhoBTB3, we threaded the
sequence of its Rho domain onto that of RhoA-GMPPNP (PDB
1KMQ). If we used RhoA’s precise orientation of bound GTP or
ATP, the imido-ring of either base showed steric clash within
the nucleotide-binding pocket (not shown). However, a small
(10), outward rotation of the glycosidic linkage was all that
was required to position the adenosine at a position that enables
optimal hydrogen binding to the catalytically important N138
(Figures 6D, right column and 6E). Indeed, ATP would fit snugly
and favorably into the binding pocket under this hypothetical
scenario. Modeling can only offer predictions about residues
that might influence nucleotide specificity: in this light, it is note-
worthy that D180 would be adjacent to the amino group on the
adenine base. Perhaps negative charge repulsion by D180 on
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makes guanine nucleotide binding less favorable.
In addition to binding ATP, RhoBTB3 can hydrolyze this nucle-
otide. RhoBTB3 readily hydrolyzed [g32P]-ATP (Figure 6F, filled
circles) at a rate of 4.5 per minute at 37C but did not hydrolyze
[g32P]-GTP (Figure 6F). For comparison, Rab5 hydrolyzes GTP
with a single turnover rate constant of 0.12 min1 at 37C (Simon
et al., 1996). The calculated Kcat/KM was 93,750 M
1min1
(Figure 6G), comparable to that of the human Hsp70 and
Hsp90 chaperones that hydrolyze ATP with rate constants of
0.6–140 per minute (Nadeau et al., 1993). In addition, binding
and hydrolysis required the unique N138 residue of RhoBTB3,
as when it was reverted to the D found in most other small
GTPases (N138D), significantly less binding (not shown) and
hydrolysis were observed (Figure 6F, open circles).
Unlike Ras-related GTPases that bind GTP very tightly (but
similar to ATPases such as Hsp90; Nadeau et al., 1993),
RhoBTB3 binds nucleotide more weakly: it’s KM for ATP is
48 mM (Figure 6G), compared with nanomolar KDs for GTPases
(cf. Simon et al., 1996). ATP is more abundant than GTP in the
cytosol, at millimolar levels that far exceed this value. In addition,
cellular interactions can alter nucleotide-binding affinity: for
example, a load on Myosin VI has been shown to change the
affinity of the motor for ADP (Altman et al., 2004). In summary,
RhoBTB30s nucleotide binding and hydrolysis properties are
similar to other cellular ATPases; as in GTPases, intrinsically
slow nucleotide hydrolysis is likely to be catalyzed by other
components.
Rab9 Relieves RhoBTB3 ATPase Autoinhibition
One role for Rab9 binding could be to regulate the ATPase activity
of RhoBTB3. To test this, we purified full-length, recombinant
His-RhoBTB3 protein (Figure 7A, right gel insert) and compared
its ATPase activity with that of the Rho domain alone. For these
experiments, we used equimolar amounts of active enzymes,
quantified by monitoring the ability of each preparation to bind
[a32P]-ATP.
As shown in Figure 7A, full-length RhoBTB3 protein (open
crosses) displayed 50% the rate of ATP hydrolysis seen for
the Rho domain alone (open squares). Satisfyingly, addition of
Rab9 GTPase (closed circles) but not Rab5 GTPase (closed dia-
monds) brought the hydrolysis rate of full-length RhoBTB3 to
that of the Rho domain alone. This suggests that the C-terminal
portion of RhoBTB3 controls the N-terminal Rho domain; binding
of Rab9 to the C terminus releases this interaction, permitting
ATP hydrolysis at an uninhibited, basal rate. These experiments
demonstrate the ability of Rab9 to regulate RhoBTB3 ATPase.
RhoBTB3 Binds TIP47 on Membranes
In membrane traffic, ATPases are used to disassemble com-
plexes. For example, the uncoating ATPase disassembles cla-
thrin after endocytosis (Sousa and Lafer, 2006) and the Vps4
ATPase disassembles ESCRT complexes important for multive-
sicular endosome formation (Babst et al., 1998; Lata et al., 2008).
To identify a substrate for RhoBTB30s action, we attempted to
isolate RhoBTB3 in complex with its substrate on native, cellular
membranes. A human K562 cell membrane fraction enriched
in Golgi and endosomes (by sucrose gradient flotation) was
subjected to blue native gel electrophoresis (Swamy et al.,
2006) in the presence of dodecyl maltoside, and the migration
of RhoBTB3 was determined by immunoblot (Figure 7B, left panel
lanes 2 and 4). Under these conditions, in the absence of SDS,
RhoBTB3 migrated at 475 kDa. RhoBTB3 was not detected in
the same amount of cytosol analyzed in parallel (Figure 7B, lanes
1 and 3). When a chemical crosslinker (DTSSP) was added,
RhoBTB3 also migrated as a larger form at550 kDa (Figure 7B,
lane 4).
Motivated by the analogy of the clathrin uncoating ATPase, we
tested if RhoBTB3 bound to TIP47. TIP47 is recruited by Rab9
onto late endosomes and packages MPRs into nascent
transport vesicles. TIP47 may also be present on the transport
vesicles that carry MPRs to the Golgi complex. As shown in the
right panel in Figure 7B, the membrane-associated, RhoBTB3
complex contains the protein TIP47. Cytosolic TIP47 gel filtered
as a hexamer (Sincock et al., 2003) but migrated as a dimer
upon blue native gel electrophoresis in dodecyl maltoside(Figure 7B, right panel, lane 1). On membranes, however, it
perfectly comigrated with RhoBTB3, in the absence or presence
of crosslinker. The size of the RhoBTB3 complex (475 kDa)
Figure 7. RhoBTB3 Is a Rab9-Regulated ATPase that Binds TIP47
(A) ATP hydrolysis was determined at the times indicated using 100 nM active
His-RhoBTB3 full-length protein or GST-Rho domain, in the absence or pres-
ence of either Rab9 (7.6 mM active protein) or Rab5 (8.25 mM active protein) and
50 mM ATP. Right inset, SDS-PAGE analysis of proteins used.
(B) Immunoblot analysis of blue native gel electrophoresis of K562 Golgi/endo-
some-enriched membranes or K562 cytosol (10 mg each). Native protein
marker migration is shown at left (kDa). Left panel, RhoBTB3; right panel,
TIP47. X-link indicates samples that were reacted with DTSSP crosslinker.
(C and D) Rab9 and ATP stimulate release of TIP47 from the RhoBTB3
complex. (C) Representative immunoblot; (D) quantitation of duplicate experi-
ments, with standard deviation.Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc. 945
could easily accommodate a TIP47 hexamer (282 kDa) plus a
RhoBTB3 dimer (138 kDa).
IF RhoBTB30s role is to release TIP47 from membranes, addi-
tion of ATP should release TIP47 from the RhoBTB3 complex
identified here. As shown in Figures 7C and 7D, addition of the
poorly hydrolyzable ATP analog ATPgS had no effect on the
amount of TIP47 in the membrane complex. However, less
TIP47 was recovered if membranes were incubated with ATP;
still less was recovered if Rab9 GTPase was added to reaction
mixtures. These data show that TIP47 is released from
membranes by a process that is stimulated by Rab9 and ATP.
Together these data implicate RhoBTB3 in TIP47 release as
part of transport vesicle uncoating at the Golgi complex.
DISCUSSION
We have revealed here the function of an orphan, distant Rho
GTPase family member, RhoBTB3, and shown that this protein
is an ATPase instead of a GTPase. RhoBTB3 is present at the
exit face of the Golgi and requires its intrinsic ability to bind
(and likely hydrolyze) ATP to carry out its normal function. The
lack of retention of nucleotide-binding consensus sequences
led several authors to assume that RhoBTB3 had lost its ability
to bind nucleotide (cf. Ramos et al., 2002; Berthold et al.,
2008a, 2008b). Instead, the protein has diverged in a manner
that enables it to accommodate a different nucleotide-binding
partner.
We identified RhoBTB3 as a protein that interacts specifically
with Rab9 GTPase and not with 52 other Rab family members.
RhoBTB3 appears to function in concert with Rab9—in facili-
tating the transport of MPRs from endosomes to the TGN.
RhoBTB3 is also needed for normal Golgi morphology. Determi-
nants in RhoBTB3 that are needed for Rab9 binding are also
essential for RhoBTB30s role in maintaining Golgi structure, as
shown by gene rescue experiments. Indeed, Rab9 binding to
the C terminus enables RhoBTB3 to display its full, N-terminal,
basal ATPase activity. Our data demonstrate that Rab9 regulates
nucleotide hydrolysis by this enzyme. Such a scenario is reminis-
cent of the regulation of kinesin’s N-terminal ATPase activity by
its C terminus: in that case, cargo binding to kinesin’s C terminus
releases an inhibitory interaction that slows basal ATP hydrolysis
(Coy et al., 1999).
A Rho ATPase
RhoBTB3 is not the first GTPase family member to have ATPase
activity. Careful evolutionary analysis of the structures of so-
called P loop GTPases segregates GTPases into two classes:
TRAFAC and SIMIBI subgroups (Leipe et al., 2002). In the
TRAFAC category, Obg GTPases, YchF (or human OLA1) has
an unusual G4 motif and was recently shown to be an ATPase
(Koller-Eichhorn et al., 2007). The kinesin family of ATPases
also lie in the TRAFAC family and are entirely missing the
conserved, nucleotide-specifying, G4 motif. In the SIMIBI group,
MinD ATPase has diverged in its G4 motif to contain TRYN
instead of the canonical NKXD. In comparison, RhoBTB3 uses
the related G4 motif sequence, TRQN.
The OLA1 ATPase retains ATP binding preference even when
its G4 motif is reverted to that of a typical GTPase (Koller-Eich-946 Cell 137, 938–948, May 29, 2009 ª2009 Elsevier Inc.horn et al., 2007). In RhoBTB3, simple reinsertion in the mutant
of the key aspartic acid residue, N138D, decreased binding of
ATP significantly and decreased the low level of observed GTP
binding even further. Thus, G4 sequences are important in
RhoBTB3 for nucleotide binding and possibly also hydrolysis.
Analogous to guanine nucleotide exchange factors, there
may be proteins that enhance the rate of adenine nucleotide
exchange: the GrpE subunit of the bacterial chaperone DnaK
functions precisely in this manner (Liberek et al., 1991);
ATPase-activating proteins are also anticipated (Lutkenhaus
and Sundaramoorthy, 2003). Similarly, the motor ATPase, kine-
sin, has a low intrinsic rate of ATP hydrolysis, and microtubules
can stimulate kinesin’s ATP hydrolysis significantly (Kuznetsov
and Gelfand, 1986). Because of RhoBTB30s relatively low
intrinsic rate of ATP hydrolysis, it is very likely to rely upon an
ATPase-activating protein to catalyze hydrolysis of ATP at the
appropriate time and/or place. It will be of interest to try to deter-
mine whether membrane-associated, but not cytosolic TIP47,
can activate RhoBTB30s ATPase activity.
A Model for RhoBTB3 in Rab9-Dependent
Vesicle Transport
Rab9 is present on late endosomes and recruits TIP47 from the
cytosol to that compartment to package MPR cargo for export
(Carroll et al., 2001; Ganley et al., 2004). Rab9 also decorates
the transport vesicles that travel from late endosomes along
microtubule tracks toward the Golgi complex (Barbero et al.,
2002). It has not been possible to determine if TIP47 remains
on transport vesicles as they move to the Golgi, as N- or C-termi-
nally tagged GFP proteins are nonfunctional, even with an addi-
tional linker included (Sincock et al., 2003). Also, >80% of TIP47
is in the cytosol (Diaz and Pfeffer, 1998), which interferes with
live-cell video microscopy. Nevertheless, it is likely that nascent
vesicles will carry this cargo recognition protein.
Once Rab9+ vesicles reach the TGN, proteins coating the
vesicle must be removed to permit subsequent membrane
fusion. We favor a model in which Rab9, on the transport vesicle,
activates RhoBTB3 when it arrives at the Golgi surface to remove
TIP47 from the vesicles and thus permit subsequent SNARE
pairing and membrane fusion. RhoBTB3 was also needed for
TGN46 retrograde transport. TIP47 does not bind to the cyto-
plasmic domain of TGN46 (Krise et al., 2000); thus RhoBTB3
would need another substrate for its action on this class of trans-
port vesicle.
If TIP47 is on the vesicles, and RhoBTB3 is on the Golgi, do our
isolated membrane complexes derive from docked vesicles?
Future experiments will shed light on the full nature of this
complex. It is of interest to note that Berthold et al. (2008b)
reported myc-RhoBTB3 in a tight perinuclear pattern (like ours)
while GFP-RhoBTB3 sometimes decorated peripheral vesicles.
Perhaps the exogenous GFP-RhoBTB3 protein is recruited onto
TIP47-coated transport vesicles, en route to the Golgi complex.
These workers also detected ubiquitylation of RhoBTB3 and
interaction with exogenously expressed, dominant-negative
Cullin3 ubiquitin ligase. The role of this interaction in membrane
traffic is not yet known.
In summary, once again, the master Rab regulators of
membrane traffic converge with the master Rho regulators of
cell migration and motility, here by a direct interaction, to coordi-
nate vesicle arrival at the Golgi complex. RhoBTB3 is a Rab9-
regulated ATPase that may function in vesicle docking by
uncoating transport vesicles at their target. How ATP hydrolysis
is then coupled to the docking process represents an important
area for future investigation.
EXPERIMENTAL PROCEDURES
RhoBTB3 was identified in a Rab9Q66LDCC two-hybrid screen (Reddy et al.,
2006). The two-hybrid Rab collection was the generous gift of Dr. Francis Barr
(Liverpool). Plasmid generation, protein production, binding, transport,
enzyme assays, and light microscopy were as described (Ganley et al.,
2008; Burguete et al., 2008; Aivazian et al., 2006). Additional details can be
found in the Supplemental Data.
Blue native PAGE-K562 membranes from the 0.8 M/1.2 M sucrose interface
or K562 cytosol were prepared as described (Diaz and Pfeffer, 1998) and
reacted with or without crosslinking with 1 mM Dithiobis(sulfosuccinimidylpro-
prionate) (DTSSP, Pierce) by incubation of 10 mg K562 membranes or cytosol
in 50 mM HEPES (pH 7.4), 150 mM KCl, 2 mM MgCl2 for 30 min at room
temperature. The reaction was quenched with 20 mM Tris for 10 min.
Membranes were washed in BN-buffer (20 mM Bis-Tris [pH 7.4], 500 mM
3-aminocaproic acid, 20 mM NaCl, 2 mM EDTA, 10% glycerol) and solublized
with 0.1% dodecyl maltoside in BN-buffer at 4C for 1 hr. Coomassie G-250
was then added to 0.025%. Samples were loaded onto 3%–12% polyacryl-
amide Bis-Tris gels (Invitrogen), transferred to PVDF, and probed with indi-
cated antibodies.
For TIP47 release, 10 mg K562 membranes were washed and incubated with
50 mM HEPES (pH 7.4), 150 mM KCl, 10 mM EDTA for 15 min at 20C. The
membranes were then pelleted and resuspended in 50 mM HEPES (pH 7.4),
150 mM KCl, 5 mM MgCl2. Either 100 mM ATPgS, ATP regeneration system
(Itin et al., 1999), or ATP regeneration system with Rab9 preloaded with GTPgS
was added at 20C for 30 min. Membranes were pelleted and resuspended in
0.1% dodecyl maltoside in BN-buffer.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and three
figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(09)00380-8.
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